Iterum Therapeutics (ITRM) Posts Earnings Results, Misses Estimates By $0.09 EPS

Iterum Therapeutics (NASDAQ:ITRM) issued its quarterly earnings data on Tuesday. The company reported ($1.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.09), MarketWatch Earnings reports. The company had revenue of $0.04 million for the quarter.

Shares of NASDAQ ITRM opened at $7.25 on Wednesday. The company has a market capitalization of $97.85 million and a P/E ratio of -1.02. Iterum Therapeutics has a 1 year low of $4.70 and a 1 year high of $13.00. The company has a debt-to-equity ratio of 0.18, a current ratio of 7.61 and a quick ratio of 7.61.

ITRM has been the subject of a number of research reports. Zacks Investment Research lowered shares of Iterum Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, February 6th. Needham & Company LLC reiterated a “buy” rating and issued a $20.00 price objective on shares of Iterum Therapeutics in a report on Monday, March 25th. Finally, Royal Bank of Canada dropped their price objective on shares of Iterum Therapeutics to $17.00 and set an “outperform” rating for the company in a report on Wednesday. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $17.00.

TRADEMARK VIOLATION WARNING: “Iterum Therapeutics (ITRM) Posts Earnings Results, Misses Estimates By $0.09 EPS” was first reported by Dakota Financial News and is owned by of Dakota Financial News. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at

About Iterum Therapeutics

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.

Read More: What is a front-end load?

Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with's FREE daily email newsletter.